Etrolizumab for induction of remission in ulcerative colitis

Moderate quality evidence suggests that etrolizumab may be an effective induction therapy for some patients with moderate to severe ulcerative colitis who have failed conventional therapy. Due to sparse data, the risk of adverse events is uncertain.

Etrolizumab is in phase III development and EU and US filings are expected in 2018 or later.